Trials / Completed
CompletedNCT03101267
A Dose-finding Study of ASP4070
Phase 2 Dose-finding Study of ASP4070 - A Randomized, Double-blind, Placebo-controlled, Dose-finding Study in Patients With Cedar Pollinosis Using an Environmental Exposure Chamber -
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study was to evaluate the efficacy, safety, and dose-response of ASP4070 vaccinated in patients with cedar pollinosis.
Detailed description
Subjects were vaccinated with ASP4070 or placebo at 2 week intervals. Clinical symptoms were evaluated after cedar pollen exposure in a chamber at 4, 8 and 12 weeks after the last vaccination to identify the timing of the onset of therapeutic effect.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASP4070 | Intradermal vaccination at 2-week intervals |
| DRUG | Placebo | Intradermal vaccination at 2-week intervals |
Timeline
- Start date
- 2017-04-13
- Primary completion
- 2018-01-26
- Completion
- 2018-10-27
- First posted
- 2017-04-05
- Last updated
- 2024-11-26
- Results posted
- 2020-06-30
Locations
1 site across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03101267. Inclusion in this directory is not an endorsement.